Fig 1.
EAU, European Association of Urology; TURBT, transurethral resection of bladder tumor; CT, computed tomography.
Table 1.
Patients’ background.
Fig 2.
Recurrence-free survival (RFS), time to first recurrence in any site, and recurrence detection rate.
RFS in all patients with high-risk non-muscle-invasive bladder cancer (NMIBC) was evaluated using the Kaplan–Meier method (A). RFS between the highest-risk and high-risk without highest-risk groups was compared using the log-rank test (B). Time to first recurrence in any site in patients with high-risk NMIBC (C) and highest-risk and high-risk without highest-risk NMIBC (D) were evaluated. Intravesical recurrence detection rate (E) and upper urinary tract (UUT) recurrence and/or metastasis detection rate (F) were evaluated. *, routine surveillance was needed (≥ 1%). **, routine surveillance was not needed (< 1%). TURBT, transurethral resection of bladder tumor. EAU, European Association of Urology.
Fig 3.
Estimated surveillance cost, 10-year total surveillance cost, and detection failure.
Estimated surveillance costs per one recurrence detection (A: the European Association of Urology [EAU] guidelines-based surveillance protocol, B: the optimized surveillance protocol, and C; median costs) were evaluated. The optimized surveillance protocol promoted a 40% lower ($394,990) 10-year total surveillance cost compared to the EAU guidelines-based protocol (D). The number of patients that potentially failed recurrence detection using the optimized surveillance protocol (E). TURBT, transurethral resection of bladder tumor.